Form 4 for CTMX CytomX Therapeutics, Inc.
Accepted 2021-08-13 00:00:00 ET · period of report 2021-08-11 · accession 0001567619-21-015554 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-08-13 | 2021-08-11 | CTMX | McCarthy Sean A. | Pres, CEO, Dir | M - OptEx | $1.13 | +92.1K | 99.9K | +1,180% | +$104.1K |
| D | 2021-08-13 | 2021-08-11 | CTMX | McCarthy Sean A. | Pres, CEO, Dir | M - OptEx | $0.00 | -92.1K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-11 | M | A | 92,113 | $1.13 | 99,922 | D | — | — | (F1) Amount of securities held has been adjusted to reflect the transfer of 40 shares previously owned directly to Sean A. McCarthy 2018 Trust. |
| 2 | Derivative | Stock Option (Right to Buy) | 2021-08-11 | M | D | 92,113 | $0.00 | 0 | D | $1.13 · — to 2021-09-20 | 92,113 Common Stock | (F4) 100% of the shares subject to the option are fully vested and exercisable. |